A rush to market in the US and a trickle in Europe
This article was originally published in Clinica
Executive Summary
The defining development for medtech companies in 1996 was the rush of US development-stage businesses to the stock market during the first half of the year. This was followed by what must have been considerable disappointment for many early investors during the second half of the year when many newly-floated companies performed badly. Of the 46 initial public offerings in the US, the share price of 10 companies halved by December. Only 18 managed an increase, but three more than doubled in value between their flotation and December.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.